GSK R&D chief Hal Barron (left) and Vir CEO George Scangos
February 17, 2021 08:16 AM ESTUpdated 08:26 AM
Financing

Glax­o­SmithK­line bets an­oth­er $345M cash on Vir, ex­pand­ing Covid-19 part­ner­ship to flu, RSV and oth­er virus­es

Jason Mast

Editor

Af­ter Glax­o­SmithK­line and Vir signed their $250 mil­lion part­ner­ship last April, they quick­ly ran in­to a prob­lem.

The two were sup­posed to be work­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times